Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat for pediatric and AYA refractory solid tumors (TURTLE / NCCH2214)
jRCTs031220736Active, not recruiting
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tazemetostat in Non-hematologic malignancy, malignant rhabdoid tumor (MRT), Atypical teratoid rhabdoid tumor (ATRT) and 4 more. Primary endpoint: Objective response rate at 16 weeks. Started Mar 2023; status: active, not recruiting.
02
Drugs
tazemetostat
03
Conditions
Non-hematologic malignancymalignant rhabdoid tumor (MRT)Atypical teratoid rhabdoid tumor (ATRT)epithelioid sarcoma (ES)synovial sarcoma (SS)
Beyond the preview
Go deeper on jRCTs031220736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220736.